Skip to main navigation Skip to search Skip to main content

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

  • on behalf of the YOSEMITE and RHINE Investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)264-279
Number of pages16
JournalJapanese Journal of Ophthalmology
Volume67
Issue number3
DOIs
StatePublished - May 2023

ASJC Scopus Subject Areas

  • Ophthalmology

Keywords

  • Angiopoietin-2
  • Anti-VEGF therapy
  • Diabetic macular edema
  • Faricimab
  • Vascular stability

Cite this